ETC-206 | 1464151-33-4 | MNK1/2 inhibitor

MedKoo Cat#: 206971 | Name: ETC-206

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ETC-206 is a selective MNK1/2 inhibitor with IC50 = 64 nM (for MNK1) and IC50 = 84 nM (for MNK2). ETC-206 in combination with dasatinib prevents BC-CML LSC self-renewal in vitro and enhances dasatinib antitumor activity in vivo.

Chemical Structure

ETC-206

CAS#1464151-33-4

Theoretical Analysis

MedKoo Cat#: 206971

Name: ETC-206

CAS#: 1464151-33-4

Chemical Formula: C25H20N4O2

Exact Mass: 408.1586

Molecular Weight: 408.46

Elemental Analysis: C, 73.51; H, 4.94; N, 13.72; O, 7.83

Price and Availability

Size	Price	Availability
5mg	USD 90.00	Ready to ship
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,250.00	Ready to ship
500mg	USD 1,950.00	Ready to ship
1g	USD 2,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ETC-206; ETC 206; ETC206; Tinodasertib

IUPAC/Chemical Name

4-(6-(4-(Morpholine-4-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile

InChi Key

FWRFPHJSGLYXTD-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H20N4O2/c26-15-18-1-3-20(4-2-18)23-16-27-24-10-9-22(17-29(23)24)19-5-7-21(8-6-19)25(30)28-11-13-31-14-12-28/h1-10,16-17H,11-14H2

SMILES Code

N#CC1=CC=C(C2=CN=C3C=CC(C4=CC=C(C(N5CCOCC5)=O)C=C4)=CN32)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# A21T02K03

QC Data

View QC data: current batch, Lot# A21T02K03

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

ETC-206 is a selective MNK1 and MNK2 inhibitor with IC50s of 64 nM and 86 nM, respectively.

In vitro activity:

A comparison of the two optimized compounds, 40 and 48 (ETC-206), shows that 40 is the most potent in the enzymatic assay, but that potency did not carry over to eIF4E phosphorylation inhibition in HeLa cells, where 48 is slightly more potent. Compound 48 has a greater solubility, permeability and an excellent kinase selectivity. Reference: J Med Chem. 2018 May 24;61(10):4348-4369. https://pubmed.ncbi.nlm.nih.gov/29683667/

In vivo activity:

Levels of Pnpla2, Lipe, Agpat9, and Dgat1 mRNAs were significantly higher in AT (adipose tissue) of HFD + ETC (ETC-206) mice than in HFD controls (Figure 6A–D), which is broadly similar to observations for MNK-DKO mice. Agpat9 and Dgat1 were also higher in ETC-treated mice on the CD. Levels of ATGL and AGPAT9 proteins tended to follow similar patterns to those of the corresponding mRNAs (Figure 6E; quantified in Figure 6F,G) and thus also mirrored the situation in MNK-DKO mice (Figure 2E–G). Similar to the situation for MNK-DKO mice, levels of the Atp6, Nd1, Nd5, and Cox1 mRNAs were also elevated in gonadal AT of HFD + ETC mice compared to HFD controls, and in the cases of Nd1 and Cox1, and in drug-treated mice on the CD (Figure 7A–D). mRNAs for factors that promote mitochondrial biogenesis, Pgc1α, Nrf2, and Pparγ, also trended higher in ETC-treated HFD mice than in vehicle controls (Figure 7E–G). In line with data for MNK-DKO mice, ETC-206 treatment caused a marked decrease in the expression of Sfrp5 on the HFD (Figure 7H). PGC1α protein levels tended to be slightly elevated in samples from drug-treated animals (Figure 7I,J). Reference: Mol Metab. 2020 Dec; 42: 101054. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476876/

	Solvent	mg/mL	mM	comments
Solubility
	DMSO	66.0	161.58

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 408.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Sandeman LY, Kang WX, Wang X, Jensen KB, Wong D, Bo T, Gao L, Zhao J, Byrne CD, Page AJ, Proud CG. Disabling MNK protein kinases promotes oxidative metabolism and protects against diet-induced obesity. Mol Metab. 2020 Dec;42:101054. doi: 10.1016/j.molmet.2020.101054. Epub 2020 Jul 23. PMID: 32712434; PMCID: PMC7476876. 2. Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K. Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem. 2018 May 24;61(10):4348-4369. doi: 10.1021/acs.jmedchem.7b01714. Epub 2018 May 7. PMID: 29683667.

In vitro protocol:

1. Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K. Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem. 2018 May 24;61(10):4348-4369. doi: 10.1021/acs.jmedchem.7b01714. Epub 2018 May 7. PMID: 29683667.

In vivo protocol:

1: Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K. Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem. 2018 May 7. doi: 10.1021/acs.jmedchem.7b01714. [Epub ahead of print] PubMed PMID: 29683667.